UNITED STATES SECURITIES AND EXCHANGE COMMISSION

[]

	Washington, D.C. 20549	
	FORM 8-K	
	CURRENT REPORT	
Pursuant to Section	13 or 15(d) of the Securities Excha	nge Act of 1934
Date of Repo	ort (Date of earliest event Reported): Augus	t 9, 2016
(Exac	The Joint Corp. et Name of Registrant as Specified in Charte	er)
Delaware (State or Other Jurisdiction of Incorporation)	001-36724 (Commission File Number)	90-0544160 (I.R.S. Employer Identification Number)
	16767 N. Perimeter Drive, Suite 240 Scottsdale, AZ 85260 (Address of Principal Executive Offices)	
Regist	trant's telephone number, including area coc (480) 245-5960	le:
(Former na	me or former address, if changed since last	report)
Check the appropriate box below if the Form 8-K of the following provisions:	filing is intended to simultaneously satisfy	the filing obligation of the registrant under any
[] Soliciting material pursuant to Rule 1 [] Pre-commencement communications	Rule 425 under the Securities Act (17 CFR 4a-12 under the Exchange Act (17 CFR 240 pursuant to Rule 14d-2(b) under the Exchange pursuant to Rule 13e-4(c) under the Exchange 13e-4(c) under the Exchange 14d-2(d) under the Exchan	0.14a-12) nge Act (17 CFR 240.14d-2(b))

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2016, the Company issued a press release which includes the announcement of its financial results for the quarter ended June 30, 2016. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth in this Item 2.02 and Exhibit 99.1 with respect to the Company's financial results for the quarter ended June 30, 2016 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 9, 2016, the Company's Board of Directors appointed Peter Holt as Chief Executive Officer of the Company, effective immediately. Mr. Holt had been serving as acting Chief Executive Officer since April 27, 2016. The Board also elected Mr. Holt to serve as a director of the Company, effective immediately.

On the recommendation of the Compensation Committee, the Board increased Mr. Holt's annual salary to \$375,000.

As previously reported, Mr. Holt, age 58, has had extensive operational experience in senior management with companies that have multiple store locations and franchises. Most recently, he served as President and CEO of Tasti D-Lite LLC, a retailer of lower-fat dairy desserts. He held that position from 2013 until Tasti D-Lite was purchased by Kahala Brands in June of 2015. From 2007 through 2012, he was COO of Tasti D-Lite. While at Tasti D-Lite, among other achievements, he led the team to convert the licensed retail network into a business format franchise structure. He also led the acquisition of Planet Smoothie and managed the integration of the two brands. Prior to Tasti D-Lite, from 2005 until 2007, Mr. Holt served as Executive in Residence of Great Hills Partners, a Boston-based private equity firm. At Great Hills Partners, he was responsible for identifying, qualifying and assisting in the due diligence process of potential franchisor acquisitions. He was the Chief Operating Officer of 24Seven Vending (US), a subsidiary of the New Zealand publicly traded company, VTL Group Limited, from 2004 until 2005. At 24Seven Vending (US), Mr. Holt was responsible for all aspects of the implementation of an acquisition-to-franchise conversion expansion strategy in parallel with managing the financing, sales, operations, technology, and training for the company. From 1997 through 2003, Mr. Holt held various positions with Mail Boxes, Etc., including Executive Vice President of Franchise Sales and Development, Senior Vice President, International, and Vice President, International sales and operations division. Mr. Holt also held positions at Brice Foods, Inc. (1990-1996) and International Franchise Association (1986-1990).

There were no arrangements or understandings with any person relating to Mr. Holt's appointment as director of the Company, and there have been no related party transactions between the Company and Mr. Holt.

Item 8.01. Other Events.

On August 11, 2016, the Company issued a press release, attached hereto as Exhibit 99.1 and previously incorporated herein by reference, which includes the announcement of the appointment of Peter Holt as Chief Executive Officer of the Company and his election to the Company's Board of Directors. The preceding description of the press release is qualified in its entirety by reference to that portion of the press release which addresses Mr. Holt's appointment and election.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description

99.1 Press Release dated August 11, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

The Joint Corp.

Date: August 11, 2016

By: <u>/s/ Peter D. Holt</u>

Name: Peter D. Holt

Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit Number Description

99.1 Press Release dated August 11, 2016.

The Joint Corp. Reports Second Quarter 2016 Financial Results; Names Peter D. Holt Chief Executive Officer

The Company Added 29 Total Clinics in First Six Months

SCOTTSDALE, Ariz., Aug. 11, 2016 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT), a national operator, manager and franchisor of chiropractic clinics, today reported results for the quarter ended June 30, 2016. Concurrently, the Company's board of directors announced the appointment of Peter D. Holt as chief executive officer and as a member of the Company's board of directors, effective immediately.

Second Quarter 2016 Financial Highlights

- Revenue increased 45% in the second quarter of 2016 to \$5.0 million, up from \$3.4 million in the same quarter last year.
- System wide Comp Sales ¹ in the second quarter of 2016 were 27%.
- 341 total clinics in operation as of June 30, 2016, an increase of 10 clinics during the second quarter and an increase of 79 clinics from June 30, 2015.
- Company-owned or managed clinics increased by 7 during the second quarter of 2016, to 61 as of June 30, 2016.

"Strong revenue growth for the second quarter of 2016 was driven by the addition of 79 clinics over the last 12 months, including 38 company-owned or managed clinics," said Peter D. Holt, chief executive officer of The Joint Corp. "I am pleased to report that during the second quarter we continued the expansion of our exciting concept, made progress toward profitability and strengthened our commitment to operational excellence. As we previously mentioned, we will not be adding any additional company-owned or operated clinics for the rest of the year. This will allow our new classes of 2015 and 2016 greenfield clinics an opportunity to mature while we manage our capital and growth accordingly." Holt added, "In addition, it's an honor to be appointed CEO and to lead The Joint team into its next chapter of growth."

"I am happy to announce that the board of directors has unanimously approved Peter's appointment as CEO," said Richard Kerley, lead director of The Joint Corp. Board of Directors. "This decision was based not only on his previous executive and industry experiences, but also on the leadership qualities he has displayed while in the role of chief operating officer and acting chief executive officer of The Joint Corp. We are very pleased that Peter has accepted this position and are confident that his in-depth knowledge of our industry as well as his proven franchising and operating capabilities in the retail industry are exactly what we need to lead the organization going forward."

Second Quarter 2016 Financial Results

Revenue for the second quarter of 2016 increased 45% to \$5.0 million from \$3.4 million in the second quarter of the prior year due primarily to the addition and growth of 38 company-owned or managed clinics and the addition of 41 franchised clinics since June 30, 2015.

Cost of revenue in the second quarter of 2016 decreased 8.1% compared to the second quarter of 2015, due to a decrease in openings of franchised clinics and the termination of franchise licenses.

Selling and marketing expenses increased to \$1.2 million in the second quarter of 2016, compared to \$0.5 million in the same period last year, due to an increase in the number of company-owned or managed clinics and the timing of the Company's national marketing fund expenditures.

General and administrative expenses increased to \$5.6 million in the second quarter of 2016, compared to \$3.7 million in the second quarter of 2015. This increase was driven by additional payroll and occupancy expenses associated with having more clinics open in the second quarter of 2016 compared to the same period the prior year.

Depreciation and amortization expenses increased for the second quarter of 2016, compared to the same period last year, due to the addition of property, equipment and intangible assets in acquisitions of franchises and regional developer rights, as well as growth in the number of greenfield clinics.

Operating loss in the second quarter of 2016 was (\$3.2) million, compared to an operating loss of (\$1.9) million in the second quarter of 2015. Net loss in the second quarter of 2016 was (\$3.3) million, or (\$0.26) per share, compared to a net loss of (\$1.9) million or (\$0.19) per share in the same period last year.

Adjusted EBITDA in the second quarter of 2016 was (\$2.0) million, compared to (\$1.3) million in the same quarter the

prior year.

As of June 30, 2016, cash and cash equivalents were \$6.1 million, compared to \$16.8 million at December 31, 2015.

2016 Financial Guidance

For full year 2016, The Joint Corp. is reiterating guidance for total revenues, Adjusted EBITDA and net new clinic openings as set forth below:

- Total revenues in the range of \$19 million to \$21 million.
- Adjusted EBITDA loss in the range of \$(8.9) million to \$(8.2) million.
- Net new clinic openings in the range of 58 to 63, including greenfields which make up 8 of the 14 company-owned or managed clinics added during the first six months of 2016, and 50 to 55 franchised clinics.

¹ Comp Sales refers to the amount of sales a clinic generates in the most recent accounting period, compared to sales in the comparable period of the prior year, and (i) includes sales only from clinics that have been open at least 13 full months and (ii) excludes any clinics that have closed.

Conference Call

The Joint Corp. management will host a conference call at 5:00 p.m. ET on Thursday, August 11, 2016, to discuss the second quarter 2016 results. The conference call will be accessible by dialing 765-507-2604 or 844-464-3931 (toll-free), and referencing 58534173. A live webcast of the conference call will also be available on the investor relations section of the Company's website at www.thejoint.com. An audio replay will be available two hours after the conclusion of the call through August 18, 2016. The replay can be accessed by dialing (404) 537-3406 or (855) 859-2056. The passcode for the replay is 58534173.

Non-GAAP Financial Information

This earnings release includes a presentation of EBITDA and Adjusted EBITDA, which are non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company's underlying operating performance and operating trends. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented within the tables below. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase gain, and stock-based compensation expenses. The Company defines EBITDA as net income (loss) before net interest, taxes, depreciation and amortization expenses.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company's financial statements filed with the SEC.

Forward-Looking Statements

This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our failure to develop or acquire corporate clinics as rapidly as we intend, our failure to profitably operate corporate clinics, and the factors described in "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC. Words such as "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will" and similar expressions are intended to identify such forwardlooking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future

trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

About The Joint Corp. (NASDAQ:JYNT)

At The Joint we are reinventing chiropractic by making quality care convenient and affordable for patients seeking pain relief and ongoing wellness. Our no-appointment policy and convenient hours and locations make care more accessible, and our affordable membership plans and packages eliminate the need for insurance. With 340+ clinics nationwide and more than 3 million patient visits annually, we have become a key leader and innovator in the chiropractic profession. For more information, visit www.thejoint.com, follow us on Twitter @thejointchiro and find us on Facebook, You Tube and LinkedIn.

Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, and Tennessee, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

THE JOINT CORP. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30,		December 31,		
	2016		2015		
ASSETS	((unaudited)			
Current assets:	Φ.	6 110 5 60	Φ.	16 500 050	
Cash and cash equivalents	\$	6,118,763	\$	16,792,850	
Restricted cash		565,175		385,282	
Accounts receivable, net		1,807,783		743,239	
Income taxes receivable		38,814		70,981	
Note receivable - current portion		46,500		60,908	
Deferred franchise costs - current portion		578,800		605,850	
Prepaid expenses and other current assets		359,695		366,033	
Total current assets		9,515,530		19,025,143	
Property and equipment, net		8,171,315		7,138,746	
Note receivable, net of current portion and reserve		18,327		15,823	
Deferred franchise costs, net of current portion		1,252,950		1,534,700	
Intangible assets, net		2,727,232		2,542,269	
Goodwill		2,945,263		2,466,937	
Deposits and other assets		626,073		638,710	
Total assets	\$	25,256,690	\$	33,362,328	
LIABILITIES AND STOCKHOLDERS' EQUITY					
Current liabilities:					
Accounts payable	\$	1,135,052	\$	1,996,971	
Accrued expenses		107,093		375,529	
Co-op funds liability		104,363		201,078	
Payroll liabilities		538,688		1,493,375	
Notes payable - current portion		550,400		451,850	
Deferred rent - current portion		277,041		334,560	
Deferred revenue - current portion		2,599,896		2,579,423	
Other current liabilities		68,614		54,596	
Total current liabilities		5,381,147		7,487,382	
Notes payable, net of current portion		-		130,000	
Deferred rent, net of current portion		1,391,965		457,290	

Deferred revenue, net of current portion	3,499,387	4,369,702
Other liabilities	269,456	238,648
Total liabilities	10,541,955	12,683,022
Commitments and contingencies		
Stockholders' equity:		
Series A preferred stock, \$0.001 par value; 50,000		
shares authorized, 0 issued and outstanding, as of June 30, 2016,		
and December 31, 2015	-	-
Common stock, \$0.001 par value; 20,000,000 shares		
authorized, 13,262,016 shares issued and 12,728,016 shares outstanding		
as of June 30, 2016 and 13,070,180 shares issued and 12,536,180		
outstanding as of December 31, 2015	13,262	13,070
Additional paid-in capital	36,089,128	35,267,376
Treasury stock (534,000 shares as of June 30, 2016 and		
December 31, 2015, at cost)	(791,638)	(791,638)
Accumulated deficit	(20,596,017)	(13,809,502)
Total stockholders' equity	14,714,735	20,679,306
Total liabilities and stockholders' equity	\$ 25,256,690	\$ 33,362,328

THE JOINT CORP. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

		Three Months Ended June 30,			Six Months Ended				
				June 30,					
		2016		2015		2016		2015	
Revenues:									
Revenues and management fees from company									
clinics	\$	2,137,252	\$	783,016	\$	3,795,805	\$	1,170,469	
Royalty fees		1,428,548		1,098,190		2,797,379		2,113,704	
Franchise fees		524,209		876,259		1,039,009		1,224,259	
Advertising fund revenue		356,580		339,462		622,301		624,978	
IT related income and software fees		229,400		197,214		450,534		401,189	
Regional developer fees		225,080		50,750		372,617		268,250	
Other revenues		72,972		81,855		161,432		131,796	
Total revenues		4,974,041		3,426,746		9,239,077		5,934,645	
Cost of revenues:									
Franchise cost of revenues		668,851		743,592		1,363,586		1,251,158	
IT cost of revenues		58,888		48,226		104,116		85,921	
Total cost of revenues		727,739		791,818		1,467,702		1,337,079	
Selling and marketing expenses		1,174,178		534,298		1,912,861		1,380,924	
Depreciation and amortization		637,115		278,502		1,212,659		401,098	
General and administrative expenses		5,625,996		3,668,187		11,322,502		6,576,826	
Total selling, general and administrative expenses		7,437,289		4,480,987		14,448,022		8,358,848	
Loss from operations		(3,190,987)		(1,846,059)		(6,676,647)		(3,761,282)	
Other income (expense), net		3,075		(9,811)		7,999		1,689	
Loss before income tax expense		(3,187,912)		(1,855,870)		(6,668,648)		(3,759,593)	

Income tax expense	(73,470)	- -	(117,867)	
Net loss and comprehensive loss	\$ (3,261,382)	\$ (1,855,870)	\$ (6,786,515)	\$ (3,759,593)
Loss per share:				
Basic and diluted loss per share	\$ (0.26)	\$ (0.19) 5	(0.54)	\$ (0.39)
Basic and diluted weighted average shares	12,672,974	9,768,230	12,620,438	9,734,115
Non-GAAP Financial Data:				
Net loss	\$ (3,261,382)	\$ (1,855,870)	\$ (6,786,515)	\$ (3,759,593)
Interest expense	4,225	-	8,676	-
Depreciation and amortization	637,115	278,502	1,212,659	401,098
Income tax expense	73,470	-	117,867	-
EBITDA	\$ (2,546,572)	\$ (1,577,368)	5 (5,447,313)	\$ (3,358,495)
Stock based compensation	559,726	157,212	757,394	289,499
Acquisition related expenses	18,958	136,544	49,818	279,253
Adjusted EBITDA	\$ (1,967,889)	\$ (1,283,612)	(4,640,100)	\$ (2,789,743)

The above table presents the reconciliation of net income (loss) to Adjusted EBITDA for the three and six month periods ended June 30, 2016 and 2015.

THE JOINT CORP. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

	Six Months Ended June 30,			
		2016	_	2015
Net loss	\$	(6,786,515)	\$	(3,759,593)
Adjustments to reconcile net loss to net cash		1,636,564		180,692
Changes in operating assets and liabilities		(2,905,287)		1,035,333
Net cash used in operating activities		(8,055,238)		(2,543,568)
Net cash used in investing activities		(2,465,949)		(5,648,224)
Net cash provided by financing activities		(152,900)		(25,000)
Net decrease in cash	\$	(10,674,087)	\$	(8,216,792)

Investor Contact:
Peter Vozzo
peter.vozzo@westwicke.com
443-213-0505

Media Contact: Inna Lazarev Public Relations Manager inna.lazarev@thejoint.com